CORT Financial Facts
Basic and diluted net loss per share: 0.02Net loss and comprehensive loss: 2.59M
See Full Income Statement
Accrued clinical expenses: 6.87M
Total current liabilities: 31.68M
See Full Balance Sheet
Corcept Therapeutics (CORT) Earnings
|
Expand Research on CORT
| Next EPS Date | 11/4/26 | EPS Growth Rate | +393.8% |
|---|---|---|---|
| Average EPS % Beat Rate | +832.6% | Revenue Growth Rate | +54.6% |
| Average % Move 1-Wk after EPS | +4.6% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/4/26  |
Q326 | N/A | $0.79 | N/A | N/A | $320.88M | = | N/A | N/A | ||
| 7/29/26 |
Q226 | $0.36 | $0.01 | +$0.35 | $256.1M | $217.85M | = |  | | Details | |
| 4/30/26 | Q126 | -$0.30 | -$0.11 | -$0.19 | $164.9M | $183.28M | = | | | Details | |
| 2/24/26 | Q425 | $0.20 | $0.25 | -$0.05 | $202.12M | $249.52M | = | | | Details | |
| 2/18/26 |
Q425 | N/A | $0.25 | N/A | N/A | $249.52M | = | N/A | N/A | ||
| 11/4/25 | Q325 | $0.16 | $0.13 | +$0.03 | $207.6M | $218.53M | = | | | Details | |
| 7/31/25 | Q225 | $0.29 | $0.19 | +$0.10 | $194.4M | $199.4M | = | | | Details | |
| 5/5/25 | Q125 | $0.17 | $0.15 | +$0.02 | $157.2M | $177.94M | = | | | Details |
